Search

Search Constraints

You searched for: Author/Creator Morelli, Franco

Search Results

1. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Issue 1 (January 2022)

2. Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. (19th March 2019)

3. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

4. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. (October 2021)

5. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. (November 2020)

6. Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. (4th March 2022)

7. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). (May 2021)

8. Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease‐19 Pandemic: A Survey of International Expertise Centers. (18th September 2020)

9. PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. Issue 24 (June 2017)

10. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. (May 2019)